Horizon Pharma PLC (HZNP) Scheduled to Post Earnings on Monday
Horizon Pharma PLC (NASDAQ:HZNP) is scheduled to be releasing its earnings data before the market opens on Monday, November 6th. Analysts expect Horizon Pharma PLC to post earnings of $0.22 per share for the quarter.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to analysts’ expectations of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 EPS. On average, analysts expect Horizon Pharma PLC to post $0.73 EPS for the current fiscal year and $1.16 EPS for the next fiscal year.
Horizon Pharma PLC (NASDAQ HZNP) traded down 0.07% during trading on Monday, reaching $13.77. The company’s stock had a trading volume of 617,140 shares. The stock’s market cap is $2.25 billion. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The firm’s 50-day moving average is $13.21 and its 200-day moving average is $12.65.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Jefferies Group LLC reiterated a “buy” rating and issued a $14.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 14th. Piper Jaffray Companies set a $17.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Tuesday, July 25th. BMO Capital Markets reiterated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 28th. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.00.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.